ClinicalTrials.Veeva

Menu

An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients (SAFE)

Novo Nordisk logo

Novo Nordisk

Status

Completed

Conditions

Diabetes
Diabetes Mellitus, Type 2

Treatments

Drug: repaglinide

Study type

Observational

Funder types

Industry

Identifiers

NCT01077570
AGEE-3822
U1111-1112-6394 (Other Identifier)

Details and patient eligibility

About

This study is conducted in Asia. The aim of this observational study is, under normal clinical practice conditions, to investigate the clinical safety and effectiveness in Chinese patients with type 2 diabetes who have never received anti-diabetic treatment before.

Enrollment

2,033 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HbA1c more than 6.5%, no anti-diabetes treatment accepted before entering the study

Exclusion criteria

  • Subjects who received any anti-diabetic treatment previously
  • Known or suspected allergy to trial product(s) or related products.
  • Subjects who previously enrolled in this study.
  • Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.

Trial design

2,033 participants in 1 patient group

Repaglinide
Treatment:
Drug: repaglinide

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems